PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence

Part of paid clinical trials in Orlando, Florida.

Sponsor
AdventHealth
Study ID
NCT06617481
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Prostate Cancer (Post Prostatectomy)

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • 18F-rhPSMA-7.3 (Posluma) — DRUG
    PET Scan using Posluma for detection of early recurrence of prostate cancer.

Study Details

Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.

Key Dates

Start date
Sep 20, 2024
Status verified
Sep 2024
Primary completion
Sep 5, 2027
Completion
Oct 10, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Other: Open Label Main Arm
    Single Arm receiving PET scan with 18F-rhPSMA-7.3 (Posluma)

Primary Outcome Measure

Cancer Detection Rate [ Time Frame: 24 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
AdventHealthOrlandoFlorida32804
AdventHealth AdventHealth Oncology Research
[email protected]
407-303-2090
Guru Sonpavde, MD, MD

Find similar trials in Orlando, FL

By research site
AdventHealth· Orlando, FL

Related Studies